SLC6A19 and phenylketonuria: Clinical evaluation of JNT-517 in patients with PKU will demonstrate whether pharmacological SLC6A19 inhibition can selectively lower pathologically elevated levels of plasma Phe without affecting the homeostatic control of nonpathological amino acids.